Advent of the HIF Stabilizers: Key Considerations for Anemia of CKD Care

Hypoxia-inducible factor (HIF) stabilizers are a new class of drugs in late-stage trials that may soon shift the balance of treatment for anemia of chronic kidney disease (CKD). These oral agents are well-tolerated by patients, unlike red-cell transfusions and conventional erythropoiesis-stimulating agents (ESAs). In addition, HIF stabilizers, unlike ESAs, are able to increase hemoglobin (Hgb) levels irrespective of iron supplementation or inflammatory status.

In light of the potential of these groundbreaking emerging therapies, it is critical that nephrology clinicians are aware of the HIF stabilizers and their safety and efficacy data. This educational activity, “Advent of the HIF Stabilizers: Key Considerations for Anemia of CKD Care,” will help participants evaluate the risks and benefits of conventional anemia of CKD treatments, as well as the latest evidence and potential roles of the HIF stabilizers, so that, upon approval, they can be properly incorporated into patient care.